Table 1.
* Prospective pediatric observational trials evaluating the operating characteristics of Galactomannan testing for diagnosis of proven or probable aspergillosis
| Author Year |
Total # patients/episodes in study |
Testing Indication |
IA Definitiona | Proven or probable aspergillosis |
Sensitivity | Specificity | TP | FP | TN | FN | False positive rate b |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rohrlich 1996 | 37 | Neutropenia | Guiot 1994 Criteria | 10 | 100% | 92.6% | 10 | 2 | 25 | 0 | 7.4% |
| Sulaihan 2001 | 347 | Neutropenia | Locally defined | 9 | 100% | 89.9% | 9 | 34 | 304 | 0 | 10.1% |
| Steinbach 2007 | 64 | Neutropenia/acute GVHD | EORTC/MSG 2002 | 1 | 0% | 87% | 0 | 8 | 55 | 1 | 12.7% d |
| Hovi 2007 | 117 | Neutropenia | EORTC/MSG 2002 | 1 | 100% | 93% | 1 | 11 | 105 | 0 | 9.5% |
| Armenian 2009 | 78 | Neutropenia +/− fever/GVHD | EORTC/MSG 2008 | 3e | 100% | 98.7% | 34 | 1 | 74 | 0 | 1.3% |
| Fisher 2012 | 195 | Neutropenia | EORTC/MSG 2002 | 1 | 0% | 95% | 0 | 10 | 184 | 1 | 5.2% |
*
Table adapted with permission from Fisher et al. J Ped Inf Dis Soc 2012;1(2):103-11
a
The definition of proven or probable aspergillosis varied depending on the publication
b
Defined as the number of false positive results per total number of patients without IA
c
Case-control study design may inflate the calculated false positive rate for this study
d
After accounting for piperacillin-tazobactam exposure, the false positive rate was 8.5%.
e
All 3 probable cases required inclusion of positive GM EIA results to qualify for this designation